Preferred Label : Anti-c-Met/Anti-TROP2/Anti-CD3/Anti-CD28 Tetra-specific Antibody MDX2001;
NCIt synonyms : Tetra-specific Antibody MDX2001; c-Met x TROP2 x CD3 x CD28 Tetra-specific Antibody MDX2001; Anti-c-Met/TROP2/CD3/CD28 Tetra-specific Antibody MDX2001;
NCIt definition : A tetra-specific antibody targeting the tumor-associated antigens (TAAs) proto-oncogene
c-Met (hepatocyte growth factor receptor; HGFR) and trophoblast cell surface protein
2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1;
M1S1), the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein
and co-stimulatory molecule CD28, with potential immunostimulating and antineoplastic
activities. Upon administration, anti-c-Met/anti-TROP2/anti-CD3/anti-CD28 tetra-specific
antibody MDX2001 targets and binds to both CD3 and CD28 on T-cells, and c-Met and
TROP2 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic
T-lymphocyte (CTL) response against c-Met and/or TROP2-expressing tumor cells. c-Met,
a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays
key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.
TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression
is associated with enhanced tumor aggressiveness, metastasis, drug resistance and
increased tumor cell survival. The simultaneous binding of MDX2001 to two T cell receptors
(TCRs) and two TAAs may optimize T-cell function while preventing tumor antigen escape,
and may result in an increased T-cell-mediated tumor cell killing as compared to antibodies
that target one TCR and one TAA.;
Molecule name : MDX 2001; MDX-2001;
Origin ID : C208342;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
